Skip to content
Home/Our innovation /Focus areas/Pulmonary hypertension

Pulmonary Hypertension

At Johnson & Johnson, we continue to build on our decades-long effort to transform pulmonary arterial hypertension (PAH) from a deadly disease into a manageable condition to help patients live better everyday lives.
Expand
We want to reach more patients living with PAH earlier and support them in accessing best-in-class foundational oral therapies. We are continuously searching to advance the standard of care as well as finding new therapy options to complement our comprehensive portfolio which already covers the European Respiratory Society/European Society of Cardiology Guidelines.
Collapse
Our vision is to transform pulmonary hypertension (PH) into a long-term, manageable condition, so that patients can live a normal life.
Focus areas
Related stories
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine
Related links